XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 46.65

Change

-0.64 (-1.35)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.80 (-1.18%)

USD 41.35B
FHLC Fidelity® MSCI Health Care In..

-0.85 (-1.17%)

USD 2.95B
FXH First Trust Health Care AlphaD..

-1.37 (-1.24%)

USD 1.22B
XHE SPDR® S&P Health Care Equipme..

-1.19 (-1.34%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.39 (-1.58%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.71 (-1.78%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

-1.52 (-1.58%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.34 (-1.17%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.76 (-1.20%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.67 (-2.19%)

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -43.96% 43% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.96% 43% F 15% F
Trailing 12 Months  
Capital Gain -35.55% 43% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.55% 43% F 15% F
Trailing 5 Years  
Capital Gain -38.13% 33% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.13% 33% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -0.63% 14% F 31% F
Dividend Return 0.07% 19% F 23% F
Total Return 0.69% 68% D+ 16% F
Risk Return Profile  
Volatility (Standard Deviation) 15.54% 62% D 64% D
Risk Adjusted Return 0.42% 19% F 23% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.